Patient-Derived 3D Spheroid Cultures for Organ-Confined Prostate Cancer Research

Study Background and Research Question

Prostate cancer (PCa) is the most prevalent cancer among men and a leading cause of cancer-related mortality worldwide. Despite significant advances in early detection and molecular understanding, translational research aiming to improve patient outcomes is hampered by the lack of representative preclinical models of organ-confined disease. Most established PCa cell lines are derived from metastatic lesions, which poorly reflect the biology of localized tumors encountered in clinical practice. This gap has prompted the search for novel in vitro systems that can better recapitulate the heterogeneity and microenvironment of primary prostate tumors. The reference study by Linxweiler et al. (Journal of Cancer Research and Clinical Oncology) addresses this unmet need by developing patient-derived, three-dimensional (3D) spheroid cultures from radical prostatectomy (RP) specimens.

Key Innovation from the Reference Study

The principal innovation of this research lies in successfully generating and maintaining multicellular 3D spheroid cultures directly from human RP tissue samples representing organ-confined PCa. Unlike conventional monolayer cultures or metastatic cell lines, these spheroids preserve the architectural complexity and intra-/intertumoral heterogeneity seen in primary tumors. This model enables the study of tumor biology and pharmacological responses in a more physiologically relevant context, offering new opportunities for translational prostate cancer research.

Methods and Experimental Design Insights

The study included tissue samples from 173 patients undergoing radical prostatectomy. The workflow began with careful excision of cancerous tissue by a uropathologist, followed by mechanical and enzymatic disaggregation. Sequential filtration through 100 μm and 40 μm cell strainers enriched for multicellular spheroids, which were then cultured in a modified stem cell medium. The spheroids were assessed for viability (via live/dead assays), cellular composition (immunohistochemistry for markers such as CK5, CK8, AMACR, PSA, Ki67, AR, αSMA, Vimentin, and E-Cadherin), and secretory function (PSA measurement in culture supernatants).

Drug sensitivity assays were performed using four agents: docetaxel (a microtubule inhibitor), bicalutamide and enzalutamide (androgen receptor antagonists), and abiraterone (a CYP17 inhibitor). Spheroid viability was monitored to evaluate the impact of each drug, providing a direct measure of pharmacological response in this model.

Core Findings and Why They Matter

From the initial cohort, 109 patient-derived samples formed viable spheroids, with successful maintenance in culture for several months. Immunohistochemical analysis revealed consistent positivity for androgen receptor (AR), CK8, and AMACR in nearly all samples, reflecting luminal epithelial differentiation typical of organ-confined PCa. E-Cadherin positivity was also common, indicating preserved cell adhesion and tissue architecture. The spheroids could be cryopreserved and thawed while retaining viability, enhancing their utility for experimental workflows.

Pharmacological testing yielded several important insights. While docetaxel had only a moderate effect and abiraterone (a potent CYP17 inhibitor) showed no significant impact on spheroid viability, both bicalutamide and enzalutamide markedly reduced spheroid viability. This suggests that, in this model of organ-confined PCa, androgen receptor pathway blockade with competitive antagonists is more effective at suppressing tumor cell viability than CYP17 inhibition or microtubule disruption. These findings underscore the value of patient-derived 3D cultures for capturing clinically relevant drug responses and for dissecting mechanisms of androgen receptor activity inhibition in prostate cancer research (reference).

Comparison with Existing Internal Articles

Several internal articles have addressed the use of CYP17 inhibitors, particularly abiraterone acetate, in advanced prostate cancer models. For example, the article "Abiraterone Acetate: Optimizing CYP17 Inhibition in Prostate Cancer Models" outlines methods for robust androgen biosynthesis pathway inhibition in both 2D and 3D systems, including protocol enhancements for patient-derived spheroids. Another resource, "Abiraterone Acetate as a CYP17 Inhibitor in 3D Prostate Models", offers best practices for maximizing the reliability of CYP17 inhibition assays in translational workflows.

While these resources emphasize the mechanistic and technical aspects of using abiraterone acetate in advanced and castration-resistant prostate cancer (CRPC) research, the current reference study specifically addresses its effect—or lack thereof—on spheroids from organ-confined PCa. This distinction highlights the importance of model selection when assessing drug efficacy. The findings further suggest that the androgen biosynthesis pathway, though central in advanced disease, may play a less dominant role in primary, organ-confined tumors under ex vivo conditions, compared to direct androgen receptor antagonism.

Limitations and Transferability

Despite the strengths of the 3D spheroid model, several limitations should be acknowledged. First, not all patient samples yielded viable spheroids (only 109 out of 173), primarily due to low tumor content or insufficient spheroid formation. Second, the absence of a significant abiraterone effect may reflect the culture conditions, the specific biology of organ-confined PCa, or the lack of exogenous androgen supplementation. Third, while the model captures much of the relevant tumor microenvironment, certain stromal and immune components are underrepresented. Therefore, while this system provides a valuable platform for drug testing and mechanistic studies, results may not fully translate to the in vivo setting or to metastatic/CRPC contexts.

Protocol Parameters

• Tissue Processing: Immediate mechanical disintegration and limited enzymatic digestion of RP samples preserves cell viability and heterogeneity.
• Spheroid Enrichment: Sequential filtration through 100 μm and 40 μm strainers selects for multicellular aggregates suitable for culture.
• Culturing Medium: Modified stem cell medium supports long-term viability of primary prostate epithelial spheroids.
• Viability Assessment: Live/dead assays and PSA secretion measurements track spheroid health and function over time.
• Drug Testing: Spheroids can be exposed to pharmacological agents (e.g., bicalutamide, enzalutamide, abiraterone) with viability assessed after several days; concentrations and exposure durations should be optimized based on model sensitivity and drug properties.
• Cryopreservation: Spheroids tolerate standard cryopreservation protocols, enabling batch processing and long-term storage.

Research Support Resources

To facilitate advanced prostate cancer research using 3D spheroid or organoid models, researchers can employ well-characterized CYP17 inhibitors. Abiraterone acetate (SKU A8202, APExBIO) is a potent and selective steroidal CYP17 inhibitor, developed as a 3β-acetate prodrug to improve solubility and bioavailability. It is widely used for androgen biosynthesis pathway studies in both cell-based and animal models of prostate cancer, including castration-resistant and advanced disease. For detailed protocol guidance and troubleshooting in 3D spheroid assays, see the internal guides referenced above. Researchers should follow manufacturer recommendations for storage and handling to ensure experimental reliability, and tailor drug concentration and exposure parameters to the specifics of their chosen model system.